Clinical Trial RESULTS

Research Sponsor: AstraZeneca AB

Drugs Studied: Dapagliflozin and metformin

National Clinical Trial #: NCT02722239

Eudra CT #: 2015-000448-41

Protocol #: D1691C00012

Study Date: March 2016 to April 2016

Short Study Title: A study to compare 2 similar doses of dapagliflozin and metformin in healthy volunteers when taken as a single tablet or in multiple tablets manufactured by different companies

Thank you!

As a clinical study participant, you belong to a large community of participants around the world. You help researchers answer important health questions and discover new medical treatments.

Thank you for taking part in the clinical study for the drugs dapagliflozin and metformin. These drugs are approved to treat type 2 diabetes. You and all of the participants helped researchers learn how dapagliflozin and metformin affect the body.

AstraZeneca MC Russia, the sponsor of this study, thanks you for your help and thinks it is important for you to know the results of your study. An independent non-profit organization called CISCRP prepared this summary of the study results for you with the help of a medical writing organization. We hope it helps you understand and feel proud of your important role in medical research. If you have questions about the results, please speak with the doctor or staff at your study site.